Medical Device News Magazine

Esssex and Henlius Signed Amendment Agreement for Global Co-Development and Exclusive License Agreement for the Treatment of Age-related Macular Degeneration

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Essex Bio-Technology Ltd (“Essex” or the “Group”, Stock Code: 1061.HK) today announced that two of its wholly-owned subsidiaries, Essex Bio-Investment Limited (“Essex Bio-Investment”) and Zhuhai Essex Bio-Pharmaceutical Co. Ltd (“Zhuhai Essex”), signed an amendment agreement (the “Amendment Agreement”) with Shanghai Henlius Biotech, Inc. (“Henlius”, Stock Code: 2696.HK) in relation to a global Co-Development and Exclusive license Agreement signed in October 2020 (the “Agreement”). Pursuant to the Agreement, Essex Bio-Investment and Henlius will co-develop the bevacizumab HLX04 (the “Product” or “EB12-20145P”) for treatment of ophthalmic diseases such as exudative (wet) Age-related Macular Degeneration (wAMD). Essex Bio-Investment has an exclusive global license to develop, manufacture, and commercialise the Product in the field of human ophthalmic therapeutic use and/or therapies.

Reasons for, and benefits of, the entering into the Amendment Agreement

As a result of the (i) increased cost of clinical trial operations; (ii) increased cost of patient recruitment for the clinical trial programme; (iii) general inflation in the global economy and manpower shortage in the healthcare sector during and following the COVID-19 pandemic; and (iv) increased cost associated with the establishment of new clinical trial sites in the United States and Europe to support and balance requirements imposed by various regulatory authorities for the clinical trials, the development costs of the Product have materially increased since the signing of the Agreement. Therefore, to tackle the increasing development costs and to support the continuous research and development of the Product further, Essex Bio-Investment has agreed to provide additional funding towards Henlius by entering into the Amendment Agreement.
Amended terms

(i) Payments for regulatory and commercial sales milestones

(a) The regulatory milestone payment from Essex Bio-Investment to Henlius payable upon the completion of the clinical trial programme has been adjusted from US$10,000,000 (equivalent to approximately HK$78,400,000) or its Renminbi equivalent to US$8,000,000 (equivalent to approximately HK$62,720,000) or its Renminbi equivalent.

(b) The amount to be paid by the Licensee to the Licensor after the commercialisation of the Licensed Products, in the event where the Licensee commercialises the Licensed Product by itself only, shall be adjusted as follows:

Commercial sales milestone payments (which shall be paid once only) of US$1,500,000 (adjusted downwards from US$3,000,000 in the Agreement, equivalent to approximately HK$11,760,000), and US$7,500,000 (adjusted downwards from US$15,000,000 in the Agreement, equivalent to approximately HK$58,800,000).

(ii) Development costs

The arrangement of development costs will be amended as follows:

Subject to the terms of the Agreement and the Amendment Agreement, the Licensee has agreed to share the development costs with the Licensor in the aggregate amount up to US$55,000,000 (adjusted upwards from US$30,000,000, equivalent to approximately HK$431,200,000) as to 80% by the Licensee (i.e., up to US$44,000,000 (equivalent to approximately HK$344,960,000) (“Amended Essex Funding”)) and as to 20% by the Licensor. The Amended Essex Funding shall be payable in accordance with the funding schedule agreed with reference to the achievement of the specified milestones.

All other principal terms of the Agreement remain unchanged.

Current status

Currently, the EB12-20145P (HLX04-O) project has completed first patient dosing in the EU, Australia, and the US, and has been licensed for clinical trials in Singapore and other countries and regions. Essex and Henlius will progressively jointly manage the global multi-centred clinical trials of EB12-20145P (HLX04-O) and apply marketing authorisation in China, Australia, the EU, the US, and ASEAN around the globe based on the research results. EB12-20145P (HLX04-O) has the potential to be one of the first bevacizumab products approved for use in ophthalmic diseases, benefiting more patients with eye diseases worldwide.

Essex’s Board believes that Essex Bio-Investment entering the Amendment Agreement with Henlius will provide assurance that the clinical trial programme under the Agreement will remain undisrupted under Essex and Essex Bio-Investment’s control with the intent of moving towards progressive completion of the clinical trial programme within the scope of the clinical trial programme.

Medical Device News Magazine
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”